Allergan, Inc.: Another Billion-Dollar Buyout Target

Before you go, we thought you'd like these...
Before you go close icon

Earlier this week, investors following the pharmaceutical industry may have been surprised to hear that Pfizer was interested in acquiring AstraZeneca. However, the billion-dollar buyout news didn't stop there.

Yesterday, shares of Allergan , the company best-known for its key product Botox, popped more than 15% on news that Valeant Pharmaceuticals is keen on acquiring it. In the following video, analysts Max Macaluso and Michael Douglass discuss this potential deal, and its implications for investors.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

The article Allergan, Inc.: Another Billion-Dollar Buyout Target originally appeared on

Max Macaluso, Ph.D. has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading